Redx Pharma (GB:REDX) has released an update.
Redx Pharma’s CEO, Lisa Anson, has recently invested in the company by purchasing 189,500 ordinary shares at an average price of 10.01 pence each, raising her total holdings to 0.19% of the firm’s issued share capital. This move demonstrates her confidence in the biotechnology firm, which specializes in developing targeted therapeutics for fibrotic diseases and cancer, with several promising drug candidates in various stages of clinical trials.
For further insights into GB:REDX stock, check out TipRanks’ Stock Analysis page.
